EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors

Heiko Babel iD, Priya Brunsdon iD, Benjamin Engelhardt, Vanessa Schmitt iD, Christine Ratajczak iD, Sven Mensing iD, Rajeev M Menon iD, Apurvasena Parikh iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-03 · 15 (3)

DOI: 10.1002/psp4.70219 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 26.02.2026. Verfasst von Heiko Babel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Deutschland GmbH Co. KG, North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Immunoconjugates, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Telisotuzumab vedotin (Teliso‐V) is a c‐Met‐directed antibody‐drug conjugate that delivers a cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) payload to c‐Met‐expressing tumor cells. It received accelerated approval from the US FDA for the treatment of adults with locally advanced or metastatic non‐squamous non‐small cell lung cancer (NSCLC) with high c‐Met protein overexpression (≥ 50% of tumor cells with strong [3+] staining) at a dose of 1.9 mg/kg every 2 weeks (Q2W; maximum 190 mg for patients ≥ 100 kg) as an intravenous infusion. Population pharmacokinetic (PK) modeling used pooled data from a phase 1 ( N = 35) and phase 2 study ( N = 269) to describe the Teliso‐V conjugate and unconjugated MMAE PK and evaluate the impact of intrinsic and extrinsic factors on exposures in patients with solid tumors. Body weight, race, albumin, and anti‐drug antibody status were identified as significant covariates on Teliso‐V conjugate clearance, but did not result in clinically meaningful changes in exposure. The exposure‐response evaluations for efficacy (based on the pivotal phase 2 study) showed significant correlations between conjugate exposure and overall response rates. Higher conjugate exposures were also correlated with improved progression‐free survival and overall survival, demonstrating meaningful clinical benefit with the 1.9 mg/kg Q2W dosing regimen. Exposure‐safety evaluations showed significant relationships between conjugate exposures and grade ≥ 2 and grade ≥ 3 peripheral neuropathy, and grade ≥ 2 corneal epitheliopathy. Unconjugated MMAE payload exposures were correlated with a greater probability of grade ≥ 3 treatment‐emergent adverse events. The 1.9 mg/kg Q2W dose maximized efficacy while balancing adverse events in patients with c‐Met overexpressing NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metImmunoconjugatesCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsAntibodies, MonoclonalHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overModels, BiologicalDose-Response Relationship, DrugAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

MMAENSCLCantibody‐drug conjugate

Substanzen

Proto-Oncogene Proteins c-metImmunoconjugatestelisotuzumab vedotinMET protein, humanAntineoplastic AgentsAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Deutschland GmbH Co. KG, North Chicago, Illinois, USA.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
  • Oncology Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.

ORCID-Profile: Heiko Babel, Priya Brunsdon, Vanessa Schmitt, Christine Ratajczak, Sven Mensing, Rajeev M Menon, Apurvasena Parikh

Zitieren

APA

Babel, H., Brunsdon, P., Engelhardt, B., Schmitt, V., Ratajczak, C., Mensing, S., Menon, R. M., & Parikh, A. (2026). Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors. CPT: Pharmacometrics & Systems Pharmacology, 15(3). https://doi.org/10.1002/psp4.70219

Vancouver

Babel H, Brunsdon P, Engelhardt B, Schmitt V, Ratajczak C, Mensing S, et al. Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(3). doi:10.1002/psp4.70219

BibTeX
@article{Babel2026,
  author = {Babel, Heiko and Brunsdon, Priya and Engelhardt, Benjamin and Schmitt, Vanessa and Ratajczak, Christine and Mensing, Sven and Menon, Rajeev M and Parikh, Apurvasena},
  title = {Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/psp4.70219}
}
Kostenlos starten →